Shares of the fifth largest pharmaceutical company in the Indian market with a dominant position in the therapy areas of anti-infectives, gastrointestinal, pain management drugs and supplements are in focus on Monday, after SBI Mutual Fund bought shares worth a total of around Rs. 300.3 crores in the company via a bulk deal.
Price Movement
With a market capitalisation of Rs. 54,966.4 crores, the shares of Alkem Laboratories Limited hit an intraday high at Rs. 4,621.7, up by nearly 0.4 percent, as compared to its previous closing price of Rs. 4,605.65.
The stock has delivered negative returns of nearly 9.3 percent in the last one year, as well as around 9 percent returns in the last one month.
What’s the News
As per the latest block deal available with the NSE, SBI Mutual Fund bought nearly 6.41 lakh equity shares, equivalent to a 0.5 percent stake, in Alkem Laboratories through an open market transaction for about Rs. 300.3 crores, at an average price of Rs. 4,680 per share.
Also read: Penny stock jumps 5% after receiving ₹7.80 Cr worth order for water supply project
Previous News
7th February: The company acquired a 100% stake in Adroit Biomed Limited through a binding term sheet for Rs. 140 crores payable in two tranches.
The acquisition is for the expansion into the Dermatology & Cosmetology segment in the following manner: Expansion of the portfolio, Increased market reach and penetration, and Omni Channel presence.
Financials
Alkem Lab reported a marginal growth in revenue from operations, experiencing a year-on-year increase of nearly 1.5 percent, rising from Rs. 3,323.8 crores in Q3 FY24 to Rs. 3,374.3 crores in Q3 FY25.
Likewise, during the same period, the company’s net profit increased from Rs. 595 crores to Rs. 626 crores, representing a growth of around 45 percent YoY.
EBITDA for Q3 FY25 increased by 7.3 percent YoY to Rs. 760 crores, up from Rs. 707.6 crores in Q3 FY24, while the operating EBITDA margins also rose to 22.5 percent, from 21.3 percent, over the same period.
About the Company
Incorporated in 1973, Alkem Laboratories Limited is a leading Indian pharmaceutical company and the fifth largest pharmaceutical company in the Indian market, with a dominant position in the therapy areas of antiinfectives, gastrointestinal, pain management drugs and supplements.
The company is engaged in the pharmaceutical business with global operations, along with developing, manufacturing and selling pharmaceutical products.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
